AegirBio AB Logo

AegirBio AB

ISIN: SE0014401121 | Ticker: AEGIR | LEI: 549300MWGS283WZLYI10

About AegirBio AB

Company Description

AegirBio is a Swedish diagnostics company that was founded to offer tests to monitor and optimize the dosage of biological drugs via its’ unique patented technology platform. Biological drugs are the segment within the pharmaceutical industry where use is growing the fastest.

Meanwhile, drug levels vary enormously (up to 100-fold) in patients receiving standard doses of biological drugs. "One size fits all" results in patients with low drug levels not responding to treatment, while excessive drug levels increase the risk of serious side effects. In approximately 55 percent of cases, this uncertainty in dosing leads to over- or underdosing, which results in unnecessary costs, inadequate results and a higher proportion of patients with severe side effects.

Year founded


Served area



Sölvegatan 43 A, 223 70 Lund – Sweden

Filings & Publications

Shareholder information

Shares outstanding



June 26, 2020

Stock exchange(s)

Nasdaq Stockholm



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.